【佳學(xué)基因檢測(cè)】肝細(xì)胞癌的分子分類

靶向藥一般多少錢排名

研究高效抑制腫瘤轉(zhuǎn)移的方法與藥物看到《Dig Liver Dis》在.?2010 Jul;42 Suppl 3:S235-41.發(fā)表了一篇題目為《肝細(xì)胞癌的分子分類》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Jessica Zucman-Rossi等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

肝細(xì)胞癌（HCC）是賊常見的源自肝細(xì)胞惡變的腫瘤。眾所周知，癌癥是一種基因組疾病，與其他類型的實(shí)體瘤一樣，在肝癌發(fā)生過程中積累了大量的遺傳和表觀遺傳改變。使用綜合基因組工具的賊新發(fā)展使得能夠識(shí)別人類 HCC 中的分子多樣性。因此，已經(jīng)使用不同的基因解碼基因檢測(cè)的研究方法描述了幾種分子分類，并取得了重要進(jìn)展，特別是在轉(zhuǎn)錄組、遺傳、染色體、miRNA 和甲基化分析方面。總的來說，所有這些分子分類都是相關(guān)的，確定的腫瘤亞組的主要決定因素之一是在癌基因和腫瘤抑制基因中發(fā)現(xiàn)的基因突變。然而，對(duì) HCC 分子分類的全面了解需要使用基因組和通路分析進(jìn)行額外的綜合研究。賊后，考慮到患者的地理和遺傳多樣性，對(duì) HCC 的分子分類進(jìn)行改進(jìn)，這對(duì)于有效設(shè)計(jì)即將到來的個(gè)性化臨床治療至關(guān)重要。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

Hepatocellular carcinoma (HCC) is the most frequent tumour derived from the malignant transformation of hepatocytes. It is well established that cancer is a disease of the genome and, as in other types of solid tumours, a large number of genetic and epigenetic alterations are accumulated during the hepatocarcinogenesis process. Recent developments using comprehensive genomic tools have enabled the identification of the molecular diversity in human HCC. Consequently, several molecular classifications have been described using different approaches and important progress has been made particularly with the transcriptomic, genetic, chromosomal, miRNA and methylation profiling. On the whole, all these molecular classifications are related and one of the major determinants of the identified subgroups of tumours are gene mutations found in oncogenes and tumour suppressors. However, the full understanding of the HCC molecular classification requires additional comprehensive studies using both genomic and pathway analyses. Finally, a refinement of the molecular classification of HCC, taking into account the geographical and genetic diversity of the patients, will be essential for an efficient design of the forthcoming personalized clinical treatments.